AbbVie Q2 2026 earnings landed well ahead of the prior year, with the North Chicago pharmaceutical company reporting worldwide net revenues of $16.990 billion for the quarter ended June 30, 2026, up 10.2 percent on a reported basis and 9.5 percent operationally. The result was driven largely by continued momentum across AbbVie’s immunology franchise, alongside contributions from neuroscience, oncology and aesthetics. GAAP diluted earnings per share came in at $2.03, up 290.4 percent year over year, while adjusted diluted EPS reached $3.65, up 22.9 percent, even after absorbing an unfavorable $0.17 per share impact tied to acquired IPR&D and milestones expense.
Chairman and chief executive officer Robert A. Michael framed the quarter as another step in a broader growth story. He said AbbVie delivered an excellent quarter marked by strong execution and pipeline advancement, and pointed to the newly announced acquisition of Apogee Therapeutics as a move that strengthens the company’s ability to deliver innovative medicines while bolstering its immunology leadership. Michael added that AbbVie’s long-term outlook remains very strong given the momentum built during the period.
Beyond the headline figures, AbbVie Q2 2026 earnings reflect a business that has largely worked through the Humira patent cliff and is now leaning on newer immunology assets, a broadening neuroscience lineup and a steady aesthetics unit. The company also updated its full-year 2026 adjusted diluted EPS guidance, reflecting both operational overperformance and the anticipated dilutive effect of the pending Apogee transaction.
AbbVie Q2 2026 Earnings Show Double-Digit Revenue Growth
The immunology portfolio remained the primary engine behind the quarter, generating $8.786 billion in global net revenues, up 15.1 percent reported and 14.6 percent operationally. Skyrizi (risankizumab) alone brought in $5.505 billion, up 24.4 percent, while Rinvoq (upadacitinib) generated $2.525 billion, up 24.5 percent. Humira continued its expected decline, falling 35.9 percent to $756 million as biosimilar competition weighs on the legacy franchise.
Profitability metrics strengthened alongside the top-line gains reflected in AbbVie Q2 2026 earnings. The GAAP gross margin ratio was 74.7 percent, while the adjusted gross margin ratio reached 84.7 percent. Adjusted SG&A expense held at 21.0 percent of net revenues and adjusted R&D expense was 13.6 percent of net revenues, leaving an adjusted operating margin of 48.3 percent versus 37.9 percent on a GAAP basis. Net interest expense totaled $679 million, and the adjusted tax rate for the quarter was 14.7 percent.
Six-month results echo the same trend. For the first half of 2026, AbbVie posted net revenues of $31.992 billion, up 11.2 percent reported, with adjusted diluted EPS of $6.30 versus $5.43 a year earlier. The consistency between quarterly and half-year figures underscores that the growth captured in AbbVie Q2 2026 earnings is part of a broader multi-quarter pattern rather than a one-off.
Q2 2026 Consolidated Financial Performance — GAAP vs. Adjusted
| Metric | GAAP (Reported) | Adjusted (Non-GAAP) |
|---|---|---|
| Net revenues | $16.990 billion | — |
| Gross margin ratio | 74.7% | 84.7% |
| SG&A (% of net revenues) | 21.4% | 21.0% |
| R&D (% of net revenues) | 13.8% | 13.6% |
| Acquired IPR&D & milestones (% of net revenues) | 1.7% | — |
| Operating margin ratio | 37.9% | 48.3% |
| Net interest expense | $679 million | — |
| Tax rate | 15.5% | 14.7% |
| Diluted EPS | $2.03 | $3.65 |
Skyrizi and Rinvoq Power AbbVie Q2 2026 Earnings in Immunology
Within immunology, Skyrizi and Rinvoq together generated $8.030 billion in the quarter, dwarfing Humira’s $756 million and confirming that AbbVie’s post-Humira strategy has taken hold. Skyrizi’s growth was fairly balanced between the U.S., up 24.0 percent to $4.767 billion, and international markets, up 27.3 percent to $738 million. Rinvoq showed a similar pattern, with U.S. revenue up 21.6 percent to $1.765 billion and international revenue up 31.9 percent to $760 million.
Regulatory momentum accompanied the commercial results. AbbVie announced that the FDA and European Commission approved Skyrizi for children six and older with moderate to severe plaque psoriasis, with the FDA separately clearing Skyrizi for pediatric psoriatic arthritis, both supported by the Phase 3 OptIMMize program. Rinvoq picked up two European approvals during the quarter: one for non-segmental vitiligo, making it the first systemic EU medicine approved for that condition, and another for severe alopecia areata, backed by the Phase 3 UP-AA program.
Neuroscience also contributed to AbbVie Q2 2026 earnings, posting $3.228 billion in global net revenues, up 20.3 percent reported. Vraylar generated $1.071 billion, Botox Therapeutic delivered $1.042 billion, and the combined Ubrelvy and Qulipta migraine franchise reached $742 million. Vyalev, AbbVie’s Parkinson’s disease therapy, contributed $256 million in its early commercial ramp. The European Commission’s approval of Aquipta for acute migraine treatment, adding to its existing preventive indication, rounds out a fuller migraine portfolio.
Segment & Key Product Net Revenues – Q2 2026 vs. Q2 2025
| Segment / Product | Q2 2026 Net Revenue | Reported % Change | Operational % Change |
|---|---|---|---|
| Immunology (total) | $8.786B | +15.1% | +14.6% |
| Skyrizi | $5.505B | +24.4% | +24.0% |
| Rinvoq | $2.525B | +24.5% | +23.7% |
| Humira | $756M | −35.9% | −36.1% |
| Neuroscience (total) | $3.228B | +20.3% | +19.8% |
| Vraylar | $1.071B | +18.9% | +18.9% |
| Botox Therapeutic | $1.042B | +12.2% | +11.6% |
| Ubrelvy | $392M | +16.0% | +15.9% |
| Qulipta | $350M | +30.9% | +30.3% |
| Vyalev | $256M | >100% | >100% |
| Oncology (total) | $1.650B | −1.5% | −2.4% |
| Venclexta | $771M | +11.6% | +9.6% |
| Imbruvica | $532M | −29.4% | −29.4% |
| Elahere | $211M | +33.1% | +31.8% |
| Epkinly | $103M | +46.8% | +48.1% |
| Aesthetics (total) | $1.282B | +0.3% | −0.9% |
| Botox Cosmetic | $728M | +5.2% | +3.4% |
| Juvederm Collection | $245M | −6.0% | −6.6% |
Oncology and Neuroscience Segments Shape AbbVie Q2 2026 Earnings
Oncology was the one portfolio moving opposite the broader trend in AbbVie Q2 2026 earnings, with global net revenues of $1.650 billion, down 1.5 percent reported. Venclexta bucked the trend, rising 11.6 percent to $771 million, while Imbruvica fell 29.4 percent to $532 million amid competitive pressure. Elahere, the ovarian cancer antibody-drug conjugate, grew 33.1 percent to $211 million, and Epkinly climbed 46.8 percent to $103 million.
AbbVie’s pipeline saw significant regulatory activity that should support the segment going forward. The FDA approved Decnupaz (pivekimab sunirine) for adults with blastic plasmacytoid dendritic cell neoplasm, an ultra-rare blood cancer, marking AbbVie’s first antibody-drug conjugate approved in hematology. The European Commission authorized an expanded Venclyxto label in combination with acalabrutinib and with Imbruvica for untreated chronic lymphocytic leukemia, while Tepkinly received EU authorization alongside lenalidomide and rituximab for relapsed follicular lymphoma. AbbVie also reported topline Phase 3 EPCORE DLBCL-4 results, where chemotherapy-free Epkinly plus lenalidomide showed a statistically significant progression-free survival benefit in diffuse large B-cell lymphoma.
Regulatory & Clinical Milestones – Q2 2026
| Product | Region / Agency | Milestone | Supporting Trial |
|---|---|---|---|
| Skyrizi | FDA & EC | Pediatric (6+) plaque psoriasis approved; FDA also cleared pediatric psoriatic arthritis | Phase 3 OptIMMize |
| Rinvoq | EC | Non-segmental vitiligo — first systemic EU therapy for the condition | Phase 3 Viti-Up |
| Rinvoq | EC | Severe alopecia areata approved | Phase 3 UP-AA |
| Aquipta | EC | Acute migraine treatment approved (2nd EU indication) | Phase 3 ECLIPSE |
| Decnupaz | FDA | Approved for BPDCN — AbbVie’s first hematology ADC | Phase 1/2 CADENZA |
| Venclyxto | EC | Expanded label with acalabrutinib and Imbruvica for untreated CLL | AMPLIFY, GLOW, CAPTIVATE |
| Tepkinly | EC | Authorized with lenalidomide/rituximab for relapsed follicular lymphoma | Phase 3 EPCORE FL-1 |
| Epkinly | — | Topline Phase 3 data: PFS benefit in relapsed DLBCL | Phase 3 EPCORE DLBCL-4 |
| Skinvive by Juvederm | FDA | Approved to reduce neck lines (2nd FDA indication) | Pivotal clinical study |
| Boey (trenibotulinumtoxinE) | EC & Health Canada | Approved for glabellar lines, rapid onset | Two Phase 3 trials |
| Maviret | EC | Approved for acute HCV (ages 3+) | — |
